Role of [18F]-fluoro-2-deoxy-d-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone

References

• Engert A, Diehl V, Franklin J, . Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27:4548–4554.
   PubMed Web of Science ®Google Scholar
• Diehl V, Franklin J, Pfreundschuh M, . Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386–2395.
   PubMed Web of Science ®Google Scholar
• Aleman BM, van den Belt-Dusebout AW, Klokman WJ, . Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003;21:3431–3439.
   PubMed Web of Science ®Google Scholar
• Franklin J, Pluetschow A, Paus M, . Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006;17:1749–1760.
   PubMed Web of Science ®Google Scholar
• Josting A, Wiedenmann S, Franklin J, . Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:3440–3446.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M, . FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52–59.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Mikhaeel NG, Fields PA, . Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005;16:1160–1168.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Rigacci L, Merli F, . The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006;91:475–481.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Hutchings M, Rigacci L, . Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746–3752.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Patti C, Viviani S, . Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 2011;152:551–560.
   PubMed Web of Science ®Google Scholar
• Avigdor A, Bulvik S, Levi I, . Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. Ann Oncol 2010;21:126–132.
   PubMed Web of Science ®Google Scholar
• Dann EJ, Bar-Shalom R, Tamir A, . Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007;109:905–909.
   PubMed Web of Science ®Google Scholar
• Engert A, Eichenauer DA, Dreyling M. Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl. 4):108–109.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, . Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Mocikova H, Obrtlikova P, Vackova B, . Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study. Ann Oncol 2010;21:1222–1227.
   PubMed Web of Science ®Google Scholar
• Markova J, Kobe C, Skopalova M, . FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. Ann Oncol 2009;20:1270–1274.
   PubMed Web of Science ®Google Scholar
• Sieber M, Bredenfeld H, Josting A, . 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:1734–1739.
   PubMed Web of Science ®Google Scholar
• Juweid ME, Stroobants S, Hoekstra OS, . Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571–578.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Hutchings M, Avigdor A, . Early interim PET scan in Hodgkin lymphoma: where do we stand? Leuk Lymphoma 2008;49:659–662.
   PubMed Web of Science ®Google Scholar
• Meignan M, Gallamini A, Haioun C, . Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010. Leuk Lymphoma 2010;51:2171–2180.
   PubMed Web of Science ®Google Scholar
• Meignan M. Interim PET in lymphoma: a step towards standardization. Eur J Nucl Med Mol Imaging 2010;37:1821–1823.
   PubMed Web of Science ®Google Scholar
• Barrington SF, Qian W, Somer EJ, . Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010;37:1824–1833.
   PubMed Web of Science ®Google Scholar
• Gallamini A, O'Doherty M. Report of satellite workshop on interim-PET in Hodgkin lymphoma: 8th International Symposium on Hodgkin Lymphoma, Cologne, 23 October 2010. Leuk Lymphoma 2011;52:583–586.
   PubMed Web of Science ®Google Scholar
• Furth C, Amthauer H, Hautzel H, . Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma–results for dedicated assessment criteria in a blinded dual-centre read. Ann Oncol 2011;22:1198–1203.
   PubMed Web of Science ®Google Scholar
• Le Roux PY, Gastinne T, Le Gouill S, . Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging 2011;38: 1064–1071.
   PubMed Web of Science ®Google Scholar